Active, not recruitingPhase 1NCT05704985

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

Studying Papillary renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
DEKA Biosciences
Principal Investigator
Medical Officer
DEKA Biosciences
Intervention
DK210 (EGFR)(biological)
Enrollment
39 target
Eligibility
18 years · All sexes
Timeline
20232025

Study locations (7)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05704985 on ClinicalTrials.gov

Other trials for Papillary renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Papillary renal cell carcinoma

← Back to all trials